Vasicek Brooke, Adams William, Steadman Laryn, Reserva Jeave, Swan James
Drs. Vasicek, Reserva, and Swan are with the Division of Dermatology at the Loyola University Medical Center in Hines, Illinois.
Dr. Adams is with the Biostatistics Core, Health Sciences Division at the Loyola University Chicago in Chicago, Illinois.
J Clin Aesthet Dermatol. 2019 Jun;12(6):27-28. Epub 2019 Jun 1.
Isotretinoin treatment has been linked to flares of severe acne, which can be managed by the coadministration of systemic corticosteroids or prevented by beginning with a low dose of isotretinoin. To our knowledge, there are no estimates in the literature on the frequency of coprescription of isotretinoin and systemic corticosteroids. We sought to quantify the estimated frequency of coprescription of isotretinoin and systemic corticosteroids and assess trends of the use of isotretinoin with systemic corticosteroids for acne as they relate to age, sex, race, insurance, and provider specialty. Data from the National Ambulatory Medical Care Survey (NAMCS) from 2003 to 2015, National Hospital Ambulatory Medical Care Survey Hospital Outpatient Departments (NHAMCS-OPD) from 2003 to 2011, and National Hospital Ambulatory Medical Care Survey Hospital Emergency Departments (NHAMCS-ED) from 2003 to 2014 were aggregated for this analysis. The number of prescriptions for isotretinoin and/or systemic corticosteroids was estimated by specialty (for NAMCS) and by survey type (for NHAMCS-OPD and NHAMCS-ED). Among all first visits to a physician for acne (n=18,914,096), approximately 3.9 percent prescribed isotretinoin, 0.24 percent prescribed corticosteroids, and the remaining 96 percent prescribed neither drug. This was comparable to estimates for first visits to a dermatologist for acne (n=13,920,913), where approximately 4.2 percent prescribed isotretinoin, 0.32 percent prescribed corticosteroids, and the remaining 95 percent prescribed neither medication. Currently, isotretinoin and systemic corticosteroids are rarely prescribed together.
异维甲酸治疗与重度痤疮发作有关,可通过联合使用全身性皮质类固醇来控制,或通过起始低剂量异维甲酸来预防。据我们所知,文献中尚无关于异维甲酸与全身性皮质类固醇联合处方频率的估计。我们试图量化异维甲酸与全身性皮质类固醇联合处方的估计频率,并评估异维甲酸与全身性皮质类固醇用于治疗痤疮时与年龄、性别、种族、保险和医疗服务提供者专业相关的使用趋势。为此分析汇总了2003年至2015年的国家门诊医疗调查(NAMCS)、2003年至2011年的国家医院门诊医疗调查医院门诊部(NHAMCS-OPD)以及2003年至2014年的国家医院门诊医疗调查医院急诊科(NHAMCS-ED)的数据。异维甲酸和/或全身性皮质类固醇的处方数量按专业(针对NAMCS)和调查类型(针对NHAMCS-OPD和NHAMCS-ED)进行估计。在所有因痤疮首次就诊于医生的患者中(n = 18,914,096),约3.9%的患者开具了异维甲酸,0.24%的患者开具了皮质类固醇药物,其余96%的患者两种药物均未开具。这与因痤疮首次就诊于皮肤科医生的估计情况(n = 13,920,913)相当,其中约4.2%的患者开具了异维甲酸,0.32%的患者开具了皮质类固醇药物,其余95%的患者两种药物均未开具。目前,异维甲酸和全身性皮质类固醇很少联合处方。